

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>		Application Number	09/699,003
		Filing Date	October 26, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	3762
		Examiner Name	Patricia Bianco
		Attorney Docket Number	LEN 101 CIP CON
Sheet 1 of 1	1	of	1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner's
Signature**

DeBianca

Date Considered

6/9/06


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 15

Complete if Known

Application Number 09/699,003

Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	P. Bianco

Attorney Docket Number LEN 101 CIP CON

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
PLM		4,116,589		Rishton	09-26-1978	
		4,189,470		Rose	02-19-1980	
		4,191,182		Popovich, et al.	03-04-1980	
		4,350,156		Malchesky, et al.	09-21-1982	
		4,362,155		Skurkovich	12-07-1982	
		4,375,414		Strahilevitz	03-01-1983	
		4,581,010		Skurkovich, et al.	04-08-1986	
		4,605,394		Skurkovich	08-12-1986	
		4,620,977		Strahilevitz	11-04-1986	
		4,633,417		Wilburn, et al.	12-30-1986	
		4,634,417		Korec	01-06-1987	
		4,664,913		Mielke, et al.	05-12-1987	
		4,801,449		Balint, Jr., et al.	01-31-1989	
PLM		4,813,924		Strahilevitz	03-21-1989	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
PLM	✓	DE	3302384		Lysaght, et al.	01-25-1983		
	✓	EP	0076665		E.I. Du Pont De Nemours	01-14-1987		✓
	✓	GB	2136314		Gelman Sciences, Inc.	09-19-1984		✓
	✓	JP	56092824	ANSW	Terumo Corporation	07-27-1981		M
PLM	✓	PCT	WO 79/01121		The Government of the United States of America	12-27-1979		

Examiner's Signature *PLM* Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet

2

of

15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Riggan Lenz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
ABH		4,824,432		Skurkovich, et al.	04-25-1989	
		4,834,973		Strahilevitz	05-30-1989	
		4,865,841		Balint, Jr., et al.	09-12-1989	
		4,963,265		Okarma, et al.	10-16-1990	
		5,037,645		Strahilevitz	08-06-1991	
		5,037,649		Balint, Jr., et al.	08-06-1991	
		5,078,673		Abrams	01-07-1992	
		5,356,374		Hogan, et al.	10-18-1994	
		5,605,690		Jacobs, et al.	02-25-1997	
		5,626,843		Skurkovich, et al.	05-06-1997	
		5,643,732		Strahilevitz	07-01-1997	
		5,705,615		Lim, et al.	01-06-1998	
		5,730,713		Okarma, et al.	03-24-1998	
		5,753,227		Strahilevitz	05-19-1998	
		5,840,588		Strahilevitz	11-24-1998	
		5,869,047		Blake	02-09-1999	
		5,888,511		Skurkovich, et al.	03-30-1999	
		5,910,252		Truitt, et al.	06-08-1999	
		6,039,946		Strahilevitz	03-21-2000	
		6,197,289		Wirt, et al.	03-06-2001	
		6,221,614		Prusiner, et al.	04-24-2001	
		6,245,038		Borberg, et al.	06-12-2001	
		6,264,623		Strahilevitz	07-24-2001	
		6,287,516		Matson, et al.	09-11-2001	
		6,428,790		Boyd	08-06-2002	
ABH		6,432,405		Weinberg, et al.	08-13-2002	
ABH		6,528,057		Ambrus, et al.	03-04-2003	

Examiner's Signature

ABH

Date Considered

06/11/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 15

Complete if Known



Application Number 09/699,003

Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	P. Bianco

Attorney Docket Number LEN 101 CIP CON

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ⁴ (if known)			
		6,561,997		Weitzel, et al.	05-13-2003	
		6,569,112		Strahilevitz	05-27-2003	
		6,602,502		Strahilevitz	08-05-2003	
		6,602,993		Wallach, et al.	08-05-2003	
		6,607,501		Gorsuch	08-19-2003	
		6,607,723		Good, et al.	08-19-2003	
		6,627,151		Borberg, et al.	09-30-2003	
		6,630,315		Miwa, et al.	10-07-2003	
		6,676,622		Strahilevitz	01-13-2004	
		6,685,664		Levin, et al.	02-03-2004	
		RE 31,688		Popovich, et al.	09-25-1984	
		RE 36,755		Smith, et al.	06-27-2000	
		2001/0010818		Engle, et al.	08-02-2001	
		2001/0039392		Strahilevitz	11-08-2001	
		2002/0019603		Strahilevitz	02-14-2002	
		2002/0058031		Tung, et al.	05-16-2002	
		2002/0086276		Srivastava	07-04-2002	
		2002/0107469		Bolan, et al.	08-08-2002	
		2002/0111577		Sirimanne, et al.	08-15-2002	
		2002/0119147		Howell, et al.	08-29-2002	
		2002/0159995		Brady, et al.	10-31-2002	
		2002/0183677		Chang, et al.	12-05-2002	
		2002/0187069		Levin, et al.	12-12-2002	
		2002/0197249		Brady, et al.	12-26-2002	
		2002/0197250		Brady, et al.	12-26-2002	
		2002/0197251		Brady, et al.	12-26-2002	
		2003/0073822		Lofling, et al.	04-17-2003	
		2003/0118584		Glenn, et al.	06-26-2003	

Examiner's Signature Date Considered 

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTQ

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/699,003
		Filing Date	October 26, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	3762
		Examiner Name	P. Bianco
		Attorney Docket Number	LEN 101 CIP CON
Sheet	4	of	15


U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner's
Signature _____ Date Considered _____

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEE'S OR COMPLETED FORMS TO THIS ADDRESS. SENIT TO: Assistant General Counsel for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

15

Complete if Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
QJB	✓	ABBRUZZESE, et al., "A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: Results of a trial terminated by excessive toxicity" <i>Journal of Biological Response Modifiers</i> 9:522-527 (1990).	
	✓	ADOLF AND APFLER, "A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60kDa TNF receptor, in biological fluids" <i>J. Immunol. Meth.</i> 143:127-136 (1991).	
	✓	AJANI, et al., "Phase I and II studies of the combination of recombinant human interferon-γ and 5-fluorouracil in patients with advanced colorectal carcinoma" <i>Journal of Biological Response Modifiers</i> 8:140-146 (1989).	
	✓	ALBERTINI, et al., "Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy" <i>Journal of Biological Response Modifiers</i> 9:456-462 (1990).	
	✓	ARENDE, "Inhibiting the effects of cytokines in human diseases" <i>Adv. Int. Med.</i> 40:365-394 (1995).	
	✓	AVNER, et al., "Therapeutic murine monoclonal antibodies developed for individual cancer patients" <i>Journal of Biological Response Modifiers</i> 8:25-36 (1989).	
	✓	BALCEWICZ-SABLINSKA, et al., "Pathogenic <i>Mycobacterium tuberculosis</i> evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-α" <i>J. Immunol.</i> 161:2636-2641 (1998).	
	✓	BALIKO, et al., "Th2 biased immune response in cases with active <i>Mycobacterium tuberculosis</i> infection and tuberculin anergy" <i>FEMS Immunol. Med. Micro.</i> 22:188-204 (1998).	
	✓	BERMUDEZ AND CHAMPSI, "Infection with <i>Mycobacterium avium</i> induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice" <i>Infect. Immun.</i> 61:3093-3097 (1993).	
QJB	✓	BEUTLER AND CERAMI, "The biology of cachectin/TNF-A primary mediator of the host response" <i>Ann. Rev. Immunol.</i> 7:625-655 (1989).	


Examiner's Signature	<i>QJB</i>	Date Considered	06/11/06
----------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SLB	✓	BLAUER, et al., "Modulation of the antilisterial activity of human blood-derived macrophages by activating and deactivating cytokines" <i>J. Interferon Cytokine Res.</i> 15:105-114 (1995).	
	✓	BOMAN, et al., "Phase I study of recombinant gamma-interferon (rIFN- γ)" <i>Journal of Biological Response Modifiers</i> 7:438-446 (1988).	
	✓	BRUNTSCH, et al., "phase II study of recombinant human interferon- γ in metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:335-338 (1990).	
	✓	BUKOWSKI, et al., "Phase I trial of continuous infusion of recombinant interleukin-2 and intermittent recombinant interferon- α 2a. Clinical effects" <i>Journal of Biological Response Modifiers</i> 9:538-545 (1990).	
	✓	CAULFIELD, et al., "Phase I1-Ib trial of an anti-G _{D3} monoclonal antibody in combination with interferon- α in patients with malignant melanoma" <i>Journal of Biological Response Modifiers</i> 9:319-328 (1990).	
	✓	CHAMBRIER, et al., "Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients" <i>Journal of Biological Response Modifiers</i> 9:251-255 (1990).	
	✓	CHOUAIB, et al., "More insights into the complex physiology of TNF" <i>Immunol. Today</i> 12(5):141-145 (1991).	
	✓	COCLET-NININ, et al., "Interferon-beta not only inhibits interleukin-1 β and tumor necrosis factor- α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells" <i>Eur. Cytokine Network</i> 8(4):345-349 (1997).	
	✓	COLMAN, et al., <u>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</u> 2nd. Edition (Colman, et al., eds.) pp. 63-67 J.B. Lippincott: Philadelphia, PA, 1987.	
	✓	COX, et al., "Phase II study of human lymphoblastoid interferon in patients with multiple myeloma" <i>Journal of Biological Response Modifiers</i> 7:318-325 (1988).	
SLB	✓	CREAVEN, et al., "Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer" <i>Journal of Biological Response Modifiers</i> 9:492-498 (1990).	

Examiner's Signature	<i>SLB</i>	Date Considered	06/11/04
----------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lenz
Group Art Unit	3762
Examiner Name	P. Blanco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BLM	✓	CROGHAN, et al., "A phase I trial of recombinant interferon- α and α -difluoromethylornithine in metastatic melanoma" <i>Journal of Biological Response Modifiers</i> 7:409-415 (1988).	
	✓	D'ANDREA, et al., "Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells" <i>J. Exp. Med.</i> 178:1041-1048 (1993).	
	✓	DIMERY, et al., "Recombinant interferon- γ in the treatment of recurrent nasopharyngeal carcinoma" <i>Journal of Biological Response Modifiers</i> 8:221-226 (1989).	
	✓	DINARELLO, "Induction of interleukin-1 and interleukin-1 receptor antagonist" <i>Sem. In Oncol.</i> 24(no. 3, Suppl. 9):81-93 (1997).	
	✓	DUPERE, et al., "Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation <i>in vitro</i> " <i>Journal of Biological Response Modifiers</i> 9:140-148 (1990).	
	✗	ENGELHARDT, et al., "Biological response to intravenously administered endotoxin in patients with advanced cancer" <i>Journal of Biological Response Modifiers</i> 9:480-491 (1990)	
	✓	ENGELMANN, et al., "Two tumor necrosis factor-binding proteins purified from human urine" <i>J. Biol. Chem.</i> 265(3):1531-1536 (1990).	
	✓	ERIKS AND EMERSON, "Temporal effect of tumor necrosis factor alpha on murine macrophages infected with <i>Mycobacterium avium</i> " <i>Infect. Immun.</i> 65(6):2100-2106 (1997).	
	✓	ETGES AND MULLER, "Progressive disease or protective immunity to <i>Leishmania</i> major infection: the result of a network of stimulatory and inhibitory interactions" <i>J. Mol. Med.</i> 76:372-390 (1998).	
	✓	FAREED, et al., "Novel antigenic markers of human tumor regression" <i>Journal of Biological Response Modifiers</i> 7:11-23 (1988).	
BLB	✓	FAVROT, et al., "Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:167-177 (1990).	

Examiner's Signature	<i>P. Blanco</i>	Date Considered	06/11/06
----------------------	------------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Riggan Lenz
Group Art Unit	3762
Examiner Name	P. Blanco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CRh	✓	FERNANDES AND BALDWIN, "Interleukin-10 downregulates protective immunity to <i>Brucella abortus</i> " <i>Infect. Immun.</i> 63:1130-1133 (1995).	
	✓	FOON, et al., "A prospective randomized trial of α_{2B} -interferon/ γ -interferon or the combination in advanced metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 7:540-545 (1988).	
	✓	FROST, et al., "Interleukin-6 induction by a muramyltripeptide derivative in cancer patients" <i>Journal of Biological Response Modifiers</i> 9:160-166 (1990).	
	✓	GADDUCCI, et al., "Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer" <i>Anticancer Res.</i> 16:3125-3128 (1996).	
	✓	GILL, et al., "Interferon-alpha maintenance therapy after cytotoxic chemotherapy for treatment of acquired immunodeficiency syndrome-related kaposi's sarcoma" <i>Journal of Biological Response Modifiers</i> 9:512-516 (1990).	
	✓	GREENBLATT, et al., "The type B receptor for tumor necrosis factor-alpha" <i>Blood</i> 80:1339-1346 (1992).	
	✓	GUSTAVSON, et al., "Pharmacokinetics of teceleukin (Recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer" <i>Journal of Biological Response Modifiers</i> 8:440-449 (1989).	
	✓	HANDZEL, et al., "Immunomodulation of T cell deficiency in humans by thymic humoral factor: from crude extract to synthetic thymic humoral factor- γ 2" <i>Journal of Biological Response Modifiers</i> 9:269-278 (1990).	
	✓	HANK, et al., "Depressed <i>in vitro</i> T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following <i>in vivo</i> treatment with interleukin-2" <i>Journal of Biological Response Modifiers</i> 9:5-14 (1990).	
PLM	✓	HERCEND, et al., "Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: A feasibility trial in metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:546-555 (1990).	

Examiner's Signature

PLM

Date Considered


06/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of

15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Riggdon Lentz
Group Art Unit	3762
Examiner Name	P. Blanco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
SLB	✓	HERRMANN, et al., "Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: Assessment of two routes of administration" <i>Journal of Biological Response Modifiers</i> 9:475-479 (1990).
	✓	HERTLER, et al., "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia" <i>Journal of Biological Response Modifiers</i> 7:97-113 (1988).
	✓	HIMMLER, et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein" <i>DNA and Cell Biol.</i> 9(10):705-715 (1990).
	✓	JACOBS, et al., "minimal antigenicity of intron A in human recipients demonstrated by three analytical methods" <i>Journal of Biological Response Modifiers</i> 7:447-456 (1988).
	✓	JAKOBSEN, et al., "Decreased antitoxic activities among children with clinical episodes of malaria" <i>Infect. Immun.</i> 66(4):1654-1659 (1998).
	✓	JAKSCHIES, et al., "Emergence and decay of the human Ms homolog in cancer patients during and after interferon- α therapy" <i>Journal of Biological Response Modifiers</i> 9:305-312 (1990).
	✓	KALMANTI, et al., "Serum levels of tumor necrosis factor soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma" <i>Int. J. Hematol.</i> 57:147-152 (1993).
	✓	KAUFMANN, et al., "T cells and cytokines in intracellular bacterial infections: experiences with <i>Mycobacterium bovis</i> BCG" <i>Ciba Fdn. Symp.</i> 195:123-132 (1995).
	✓	KELLOKUMPU-LEHTINEN, et al., "Recombinant interferon- α 2a and vinblastine in advanced renal cell cancer: A clinical phase I-II study" <i>Journal of Biological Response Modifiers</i> 9:439-444 (1990).
SLB	✓	KESSLER, "Adsorptive plasma treatment: Optimization of extracorporeal devices and systems" <i>Blood Purification</i> 11:150-157 (1993).
SLB	✓	KHAZAEI, et al., "Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans" <i>Journal of Biological Response Modifiers</i> 9:178-184 (1990).

Examiner's Signature	SLB	Date Considered	06/04/06
----------------------	-----	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10

of

15

Complete if Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	P. Blanco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CLB	✓	KOLITZ, et al., "Phase I trial of recombinant interleukin-2 and cyclophosphamide: Augmentation of cellular immunity and T-cell mitogenic response with long term administration of rIL-2" <i>Journal of Biological Response Modifiers</i> 7:457-472 (1988).	Y
	✓	KRIGEL, et al., "Treatment of epidemic kaposi's sarcoma with a combination of interferon-alpha 2b and etoposide" <i>Journal of Biological Response Modifiers</i> 7:359-364 (1988).	Y
CLB	✓	LANTZ, et al., "Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans" <i>Cytokine</i> 2(6):402-406 (1990).	Y
CLB	✓	LASZLO, et al., "Phase I studies of recombinant interferon-γ" <i>Journal of Biological Response Modifiers</i> 9:185-193 (1990).	Y
		LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patología durante la infección con <i>Trypanosoma cruzi</i> " <i>Revista Argentina de Microbiología</i> , 28:99-109 (1996). <i>Not translation</i>	NO
CLB	✓	LENTZ, et al., "Apheresis of low molecular weight protein fraction and the onset of labor" <i>Journal of Clinical Apheresis</i> 5:62-67 (1990).	
CLB	✓	LENTZ, "The phylogeny of oncology" <i>Mol. Biother.</i> 2:137-144 (1990).	
	✓	LETTERIO AND ROBERTS, "Regulation of immune responses by TGF-β" <i>Ann. Rev. Immuno.</i> 16:137-161 (1998).	
	✓	LITTON, et al., "Biological and clinical effects of the oral immunomodulator 3,6'Bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy" <i>Journal of Biological Response Modifiers</i> 9:61-70 (1990).	
		LUCEY, et al., "Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases" <i>Clin. Micro. Rev.</i> 9(4):532-562 (1996).	
CLB		MAAS, et al., "Interleukin-2 in cancer treatment: disappointing or (still) promising? A review" <i>Cancer Immunol. Immunother.</i> 36:141-148 (1993).	

Examiner's Signature PLB Date Considered 06/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lenz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PLS	✓	MACA, "Inhibition of the growth of lewis lung carcinoma by indomethacin in conventional, nude, and beige mice" <i>Journal of Biological Response Modifiers</i> 9:568-580 (1990).	
	✓	MARSHALL, et al., "Effects of coumarin (12-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies" <i>Journal of Biological Response Modifiers</i> 8:62-69 (1989).	
	✓	MARSHALL, et al., "Treatment of renal cell carcinoma with daily low-dose alpha-interferon" <i>Journal of Biological Response Modifiers</i> 8:453-461 (1989).	
	✓	MILES, et al., "induction of soluble tumour necrosis factor receptors during treatment with interleukin-2" <i>Brit. J. Cancer</i> 66:1195-1199 (1992).	
	✓	MITTELMAN, et al., "Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2" <i>Journal of Biological Response Modifiers</i> 8:468-478 (1989).	
	✓	MUSIANI, et al., "Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma" <i>Journal of Biological Response Modifiers</i> 8:571-578 (1989).	
	✓	NEIDHART, "Phase I study of recombinant methionyl human consensus interferon (r-metHuIFN-Con)" <i>Journal of Biological Response Modifiers</i> 7:240-248 (1988).	
	✓	ORATZ, et al. "Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine" <i>Journal of Biological Response Modifiers</i> 8:355-358 (1989).	
	✓	ORATZ, et al., "Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: Results of a phase II trial" <i>Journal of Biological Response Modifiers</i> 9:345-354 (1990).	
PLS	✓	PAIS, et al., "Pharmacokinetics of recombinant interleukin-2 in children with malignancies: A pediatric oncology group study" <i>Journal of Biological Response Modifiers</i> 9:517-521 (1990).	

Examiner's Signature	<i>SLBianco</i>	Date Considered	06/11/00
----------------------	-----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

12

of

15

Complete If Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigidon Lentz
Group Art Unit	3762
Examiner Name	P. Blanco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CBR	✓	PAOLOZZI, et al., "Phase I trial of recombinant interleukin-2 and recombinant β -interferon in refractory neoplastic diseases" <i>Journal of Biological Response Modifiers</i> 8:122-139 (1989).	
	✓	PEREZ, et al., "A phase I trial of recombinant human gamma interferon (IFN- γ 4A) in patients with advanced malignancy" <i>Journal of Biological Response Modifiers</i> 7:309-317 (1988).	
	✓	QUESADA, et al., "Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 7:234-239 (1988).	
	✓	RABINOWITZ, et al., "Hemolytic anemia in a cancer patient treated with recombinant interferon- γ " <i>Journal of Biological Response Modifiers</i> 9:256-259 (1990).	
	✓	REIMANN, et al., "Suppression of the immune response by micro-organisms" <i>Scand. J. Immunol.</i> 31:543-546 (1990).	
	✓	RIFFKIN, et al., "Defense against the immune barrage: helminth survival strategies" <i>Immunol. Cell Bio</i> 74:564-574 (1996)	
	✓	ROMANI, et al., "T helper cell dichotomy to <i>Candida albicans</i> : implications for pathology" <i>Immunol. Res.</i> 14:148-162 (1995).	
	✓	ROSENTHAL, et al., "The <i>in vitro</i> function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2" <i>Journal of Biological Response Modifiers</i> 7:123-139 (1988).	
	✓	RYBAK, et al., "Interferon therapy of relapsed and refractory hodgkin's disease: Cancer and leukemia group B study 8652" <i>Journal of Biological Response Modifiers</i> 9:1-4 (1990).	
	✓	SARNA, et al., "Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: Clinical results" <i>Journal of Biological Response Modifiers</i> 8:16-24 (1989).	
	✓	SARNA, et al., "A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects" <i>Journal of Biological Response Modifiers</i> 9:81-86 (1990).	
AB	✓	SARTHOU, et al., "Prognostic value of anti- <i>Plasmodium falciparum</i> -specific immunoglobulin G3, cytokines, and their soluble receptors in west African patients with severe malaria" <i>Infect. Immun.</i> 65(8):3271-3276 (1997).	

Examiner's Signature	<i>CBR</i>	Date Considered	<i>06/11/01</i>
----------------------	------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Stop date for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

13

of

15

Complete if Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
clm	✓	SATO, et al., "induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy" <i>Journal of Biological Response Modifiers</i> 9:329-334 (1990).	
	✓	SCHAADT, et al., "Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma" <i>Journal of Biological Response Modifiers</i> 9:247-250 (1990).	
	✓	SCHALL, et al., "molecular cloning and expression of a receptor for human tumor necrosis factor" <i>Cell</i> 61:361-370 (1990).	
	✓	SCHEITHAUER, et al., "Combined α -2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy a induction therapy in multiple myeloma: A prospective randomized trial" <i>Journal of Biological Response Modifiers</i> 8:109-115 (1989).	
	✓	SCHILLER, et al., "A phase I trial of interferon- α -2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin" <i>Journal of Biological Response Modifiers</i> 8:252-261 (1989).	
	✓	SECKINGER, et al., "Purification and biologic characterization of a specific tumor necrosis factor α inhibitor" <i>J. Biol. Chem.</i> 264(20):11966-11973 (1989).	
	✓	SEIGLER, et al., "Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies" <i>Journal of Biological Response Modifiers</i> 8:37-52 (1989).	
	✓	SHAU, et al., "A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes" <i>Journal of Biological Response Modifiers</i> 9:71-80 (1990).	
	✓	SIDHU AND BOLLON, "Tumor necrosis factor activities and cancer therapy - A perspective" <i>Pharmacol. Ther.</i> 57:79-128 (1993).	
	✓	SIELING, et al., "Immunosuppressive roles for IL-10 and IL-4 in human infection" <i>J. Immunol.</i> 150(12):5501-5510 (1993).	
80M	✓	SPRIGGS, "One step ahead of the game: Viral immunomodulatory molecules" <i>Ann. Rev. Immunol.</i> 14:101-130 (1996).	

Examiner's Signature	<i>clm</i>	Date Considered	06/11/06
----------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

P E Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 15

Complete if Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Riggan Lentz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
(Rm)	✓ STEGER, et al., "Long-term remission in a patient with erythroleukemia following interferon- α treatment" <i>Journal of Biological Response Modifiers</i> 8:351-354 (1989).		
	✓ STEINMETZ, et al., "Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor" <i>Journal of Biological Response Modifiers</i> 7:417-423 (1988).		
	✓ SZNOL, et al., "A phase I study of high-dose interleukin-2 in combination with interferon α_{2b} " <i>Journal of Biological Response Modifiers</i> 9:529-537 (1990).		
	✓ TRIGG, et al., " α -interferon therapy for lymphoproliferative disorders developing in two children following bone marrow transplants" <i>Journal of Biological Response Modifiers</i> 8:603-613 (1989).		
	✓ TRINCHIERI, et al., "Cytokine cross-talk between phagocytic cells and lymphocytes: Relevance for differentiation/Activation of phagocytic cells and regulation of adaptive immunity" <i>J. Cell. Biochem.</i> 53:301-308 (1993).		
	✓ TRUMP et al., "Interferon- α -n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma" <i>Journal of Biological Response Modifiers</i> 9:108-111 (1990).		
	✓ UMIEL, et al., "Recombinant interleukin-2-activated intracavitary lymphocytes: Phenotypic characteristics and effector function" <i>Journal of Biological Response Modifiers</i> 8:409-421 (1989).		
	✓ VON HOFF, et al., "Phase II evaluation of recombinant γ -interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study" <i>Journal of Biological Response Modifiers</i> 9:584-587 (1990).		
✓	✓ WALSH, et al., "Phase I study of the combination of alpha-2 interferon and cisplatin" <i>Journal of Biological Response Modifiers</i> 8:11-15 (1989).		
(Rm)	✓ WEIL-HILLMAN, et al., "Transient decrease in IL-2 responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients" <i>Journal of Biological Response Modifiers</i> 7:424-437 (1988).		

Examiner's Signature *8/20/00* Date Considered 08/20/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

A circular stamp with the following text:

O I P E JC10
MAY 02 2015
PATENTS & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 15 of 15

Complete if Known	
Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigidon Lentz
Group Art Unit	3762
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

OTHER ART - NON PATENT LITERATURE DOCUMENTS

**Examiner's
Signature**

Albany

Date Considered

06/11/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.